The FDA approved Leqembi, from Japanese drugmaker Eisai, earlier this month.

本月早些时候，美国食品药品监督管理局批准了日本制药商卫材药业的仑卡奈单抗。

Eisai said it would discuss the full results from the study in late November.

日本卫材药业表示，其将在11月下旬讨论这项研究的全部结果。

And the drug approved earlier this month is called lecanemab, made by Biogen in the US and Eisai in Japan.

本月早些时候获批的新药名为莱卡内单抗，由美国的生物制药公司和日本的卫材公司生产。

Results of a clinical trial, conducted by its makers, Eisai, of Tokyo, and Biogen, of Cambridge, Massachusetts, have just been announced in the New England Journal of Medicine.

由其制造商东京卫材和马萨诸塞州剑桥市百健公司进行的临床试验结果刚刚在《新英格兰医学杂志》上公布。